Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : NIDCR
Deal Size : $2.2 million
Deal Type : Funding
Sinopia Gets SBIR Phase II Grant For Oral Mucositis Research
Details : The funding aims to support the company in discovering novel small molecules and identifying promising treatment candidates for oral mucositis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 12, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : NIDCR
Deal Size : $2.2 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : National Institute of General Medical Sciences
Deal Size : Undisclosed
Deal Type : Funding
Sinopia Secures Grant from NIGMS to Advance Metabolomics Platform
Details : The proceeds will advance its computational drug discovery LEarn And DiScover (LEADSâ„¢) platform and explore applications in oncology and immunology.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : National Institute of General Medical Sciences
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : NINDS
Deal Size : $3.3 million
Deal Type : Funding
Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase II clinical trials.
Brand Name : SB-0110
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 19, 2023
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : NINDS
Deal Size : $3.3 million
Deal Type : Funding
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : MJFF
Deal Size : $2.0 million
Deal Type : Funding
Details : The funding will be used to advance SB-0110, a novel, proprietary small molecule with a unique mechanism of action that was identified using Sinopia’s LEADS™ platform, into Phase I clinical trials.
Brand Name : SB-0110
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 19, 2023
Lead Product(s) : SB-0110
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : MJFF
Deal Size : $2.0 million
Deal Type : Funding
LOOKING FOR A SUPPLIER?